Conditions: Heart Failure
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 30
Healthy volunteers: no

Brief summary:
Anakinra ADHF is a double-blind randomized clinical trial of anakinra, recombinant human interleukin-1 receptor blocker, or placebo in patients with acute decompensated heart failure with the aim to quench the acute inflammatory response, as measured by the area-under-the-curve for C reactive protein over 14 days.

Detailed description:

Arms:
arm 1: Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14 arm 2: Placebo injections twice daily for the first 3 days then once daily for days 4-14.

Interventions: intervention 1: Anakinra (high dose) intervention 2: Anakinra (standard dose) intervention 3: Placebo intervention 4: Placebo
Intervention descriptions: intervention 1: Anakinra 100 mg daily twice daily for days 1, 2, and 3 intervention 2: Anakinra 100 mg daily for days 4-14 intervention 3: Placebo twice daily for days 1, 2, and 3 intervention 4: Placebo daily for days 4-14

Protocol document: